Antibodies, Monoclonal, Humanized

Efficacia di nirsevimab nella prevenzione del VRS: sfide e prospettive di equità

Marchetti F, Cocchi E.

2025/10 — pag. 619-620 — DOI

Impatto preliminare della profilassi universale con nirsevimab in ambito neonatale: esperienza monocentrica di Bergamo

Colombo M, Ferrari S, Mangili G

2025/6 — pag. 131-137 — DOI

Respiratory Syncytial Virus (RSV) is the main cause of hospitalisation in infants. The present single-centre observational study aimed to analyse the adherence to universal prophylaxis with Nirsevimab and to evaluate its preliminary effectiveness in ...

Nirsevimab tra presente e immediato futuro

Fusco F, Sambugaro D, Marchetti F.

2025/5 — pag. 284-288 — DOI

Un caso di pericardite recidivante colchicina-resistente

Maggio MC, Alizzi C, Di Leto E, Ippolito A, Sferlazza F, Corsello G

2023/6 — pag. 111-112 — DOI

A 9-year-old boy affected by colchicine-resistant idiopathic pericarditis was successfully treated with an IL-1 receptor antagonist (anakinra)....

La profilassi dell’infezione da virus respiratorio sinciziale: dal palivizumab al nirsevimab

Servadio M, Belleudi V, Marchetti F, Addis A.

2022/10 — pag. 632-639 — DOI

The Respiratory Syncytial Virus (RSV) is considered the leading cause of lower respiratory tract infections (LRTI) in children aged < 2 years. In high-risk children, including preterm infants, or in children with bronchopulmonary dysplasia (BPD) and ...

Il dupilumab nell’esofagite eosinofila: una nuova frontiera?

Mainetti M, Troisi A, Turlà G, Fontijn S, Rametta G, Buzzi A, Mussetto A, Marchetti F.

2022/9 — pag. 583-587 — DOI

Eosinophilic oesophagitis (EoE) is a chronic, immune-mediated or antigen-mediated oe-sophageal disease. Therapeutic first-line options currently available for EoE are elimina-tion diets, proton pump inhibitors (PPIs) and steroids. The ultimate goal o...

Tutto quello che il pediatra dovrebbe sapere sul mepolizumab

Prisco A, Carlone G, Maschio M, Badina L, Barbi E

2021/6 — pag. 374-378 — DOI

Mepolizumab, a monoclonal antibody blocking IL-5, is efficacious in the treatment of severe lung diseases sharing eosinophilic inflammation pattern. The paper describes two cases in which the drug was used with excellent results. The first involved a...

Rachitismo ipofosforemico X-linked

L. Lucchetti, D. Fintini, M. Cappa, F. Emma

2020/7 — pag. 430-436 — DOI

X-linked hypophosphatemia (XLH) is an X-linked disorder with dominant penetration, caused by mutations in the PHEX gene, which encodes for an endopeptidase that is predominantly expressed in osteoblasts, osteocytes and odontoblasts. PHEX mutations ...

Glomerulopatia da depositi di C3

S. Amoroso, M. Pennesi, A. Ventura

2018/2 — pag. 119-122

C3-glomerulopathy includes several nephropathy charac-terised by almost only C3 deposits without immunoglobu-lins with a mesangial proliferative or membrano-proliferative pattern on light microscopy. C3-glomerulopathy is determined by a dysregulation...

Quando l’asma è “difficile”: il ruolo dell’omalizumab

G. Vieni, L. Biserna, F. Marchetti

2017/3 — pag. 177-181

The percentage of asthmatic children with severe asthma is low (< 5%). Children with severe asthma require treatment with high dose of inhaled steroids plus a second controller and/or systemic steroids to control symptoms. They can also remain unco...

Il Natalizumab nel trattamento della malattia di Crohn

G. Bartolozzi

2006/1

Palivizumab: un anticorpo monoclonale umanizzato contro il virus respiratorio sinciziale

L. De Seta, G. Orso

1999/8 — pag. 491-494

Respiratory Syncytial Virus (RSV) is the main cause of respiratory infections in the first years of life. Preterm infants and those affected by broncopulmonary dysplasia (BPD) represent the categories at highest risk of severe RSV infections. Paliv...